RNAC EPS Estimates
Cartesian Therapeutics, Inc.
$6.82
+$0.14(+2.10%)
33
Overall
40
Value
30
Tech
31
Quality
Market Cap
$202.11M
Volume
214.39K
52W Range
$5.60 - $11.00
Target Price
$33.67
RNAC EPS estimates: the consensus estimate for Cartesian Therapeutics, Inc.'s current fiscal year is -$3.15 per share. Quarterly and next-year EPS forecasts, growth estimates and revenue projections follow.
RNAC EPS Estimates
- EPS estimate, current quarter
- $-1.02
- EPS estimate, next quarter
- $-1.14
- EPS estimate, current year
- $-3.15
- EPS estimate, next year
- $-4.14
- EPS growth, 3-year
- -100.00%
| Fiscal year | EPS |
|---|---|
| 2025 | $-5.02 |
| 2024 | $-4.48 |
| 2023 | $-49.80 |
| 2022 | $7.20 |
| 2021 | $-6.60 |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RNAC | $6.82 | +2.1% | 214.39K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Cartesian Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW